The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & AcquisitionsMediumUpdated•Originally published 5 May 2026•Updated 5 May 2026•

1 min read

Apimeds Pharmaceuticals Settles Dispute, Advancing Merger and $100M PIPE Financing

Key Facts

1Apimeds Pharmaceuticals US reached a comprehensive settlement with Inscobee Inc. and Apimeds Inc. resolving disputes from its December 2025 merger.

2The settlement enables the company to proceed with merger transactions and close a previously disclosed $100 million PIPE financing.

29 days ago

Version History

Version 129 days ago

What changed: Added the official ticker symbol APUS and identified Lōkahi Therapeutics as the partner for the Apitox program.

Apimeds Pharmaceuticals US, trading under the ticker APUS on the NYSE American, has reached a comprehensive settlement with Inscobee Inc. and Apimeds Inc. to resolve ongoing legal disputes. This resolution clears the path for the company to finalize its merger with MindWave Innovations Inc. and close a $100 million PIPE financing round. The secured capital is earmarked to advance the Apitox clinical program, which will now be developed in partnership with Lōkahi Therapeutics. This strategic collaboration is expected to accelerate the company's clinical roadmap and bolster its pharmaceutical operations. By removing legal hurdles and identifying key development partners, the company stabilizes its corporate structure for future growth. These updates represent a significant milestone in the firm's transition toward operational stability and market expansion.